Efficacy of Generic Imatinib After Switching from Original in Treatment of Patients with Chronic Myeloid Leukemia in the Republic of North Macedonia - A Single-Center Experience

被引：0
|
作者：
Dukovski, Dushko [1 ]
Trajkova, Sanja [1 ]
Stojanovska, Simona [1 ]
Ridova, Nevenka [1 ]
Panovska-Stavridis, Irina [1 ]
机构：
[1] Clin Hematol, Skopje, North Macedonia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CML; imatinib; selective tyrosine kinase inhibitor (TKI); chronic myeloid leukemia;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-104
引用
收藏
页码：S232 / S232
页数：1
相关论文
共 50 条
  • [21] Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia
    Demirkan, Fatih
    Sevindik, Omur Gokmen Gokmen
    Karaman, Aysegul
    Alacacioglu, Inci
    Solmaz, Serife Medeni
    Ozsan, Guner Hayri
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study
    Francis, Jose
    Palaniappan, Muthiah
    Dubashi, Biswajit
    Pradhan, Suresh Chandra
    Chandrasekaran, Adithan
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2015, 6 (01) : 30 - 33
  • [23] Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution
    Pereira, Gabriel Carvalho
    da Silva, Fernanda B.
    Oliveira, Luisa Espirito Santo
    Garibaldi, Pedro Marques
    Figueiredo-Pontes, Lorena Lobo
    Simoes, Belinda Pinto
    Palma, Leonardo Carvalho
    Traina, Fabiola
    BLOOD, 2019, 134
  • [24] Efficacy and Safety of Generic Imatinib in Chronic Phase of Chronic Myeloid Leukemia (CP-CML): Experience from a Multi-Center in China
    Zhou, Li
    Liu, Bingcheng
    Hu, Jianda
    Qu, Jianhua
    Hou, Ming
    Sun, Hui
    Jin, Jie
    Shen, Zhixiang
    BLOOD, 2019, 134
  • [25] Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center
    Dou, Xuelin
    Qin, Yazhen
    Lai, Yueyun
    Shi, Hongxia
    Huang, Xiaojun
    Jiang, Qian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (06): : E304 - E315
  • [26] Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia-Single Center Retrospective Analysis
    Bhatwadekar, Seema Shrinivas
    Deshpande, Shubhangi Vishwas
    Mehta, Arpan
    Shah, Parth
    BLOOD, 2019, 134
  • [27] Results of imatinib mesylate therapy in chronic myeloid leukemia: Experience of a single center
    Pasa, S.
    Boyraz, T.
    Beyaz, C.
    Sayar, S.
    Atayan, Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 530 - 530
  • [28] Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study
    Alsobhi, Enaam
    Abrar, Mohammed Burhan
    Abdelaal, Mohammed
    Alsaeed, Ahmed
    Absi, Ahmed
    Alzahrani, Zayed
    El-Hennaidi, Lhab
    Alshehri, Mohammed Ali
    Warsi, Ashraf
    Bayashoot, Safaa
    Hashem, Heba
    Merdad, Anas
    Radi, Suhaib
    Shiekhi, Hanadi
    Al-Amri, Abdulfattah
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 882 - 886
  • [29] Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study
    Sofia Jönsson
    Bob Olsson
    Jenny Söderberg
    Hans Wadenvik
    Annals of Hematology, 2012, 91 : 679 - 685
  • [30] Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience
    Saleem, Umera
    Hafeez, Talha
    Raza, Syed Ali
    Tahir, Muhammad
    Khalid, Fatima
    Islam, Muhammad Khurrum
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (04)
12345